logo
  

Addex Terminates Phase 2b/3 Study Of Dipraglurant In Dyskinesia Associated With Parkinson's Disease

Addex Therapeutics Ltd (ADXN) has terminated the Phase 2b/3 study, which evaluated dipraglurant as a potential treatment for dyskinesia associated with Parkinson's disease or PD-LID, due to the slow recruitment of patients. This has been attributed to the consequences of COVID-19 related patient concerns about participation in clinical studies as well as staffing shortages and turnover within study sites, the company said in a statement on Friday.

The company also said it has suspended its financial guidance, due to the termination of the dipraglurant program.

Addex stated that it now plans to focus on advancing its preclinical portfolio towards the clinic and pursuing strategic collaborations for selected programs, while it concurrently focuses on delivering under its strategic partnership with Indivior. The company's strategic partner, Janssen expects to deliver data from the Phase 2 study of ADX71149 in epilepsy patients in the fourth quarter of this year.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Longmont Colorado -based Royal Crest Dairy is recalling 2% Chocolate Milk citing the potential to be contaminated with undeclared egg, a known allergen, the U.S. Food and Drug Administration said. The recall involves Farmer's 2% Reduced Fat Chocolate Milk Pints with the code date of AUG-22. ANI Pharmaceuticals, Inc. (ANIP) Monday announced a wider loss for the second quarter, despite a 52 percent surge in revenues. For the full year 2022, the company reiterated the adjusted earnings per share range, revenue guidance and raised Cortrophin revenue outlook. The company reported a quarterly... Shares of BioNTech SE were losing around 4 percent in the morning trading in Germany and around 5 percent in the pre-market activity on Nasdaq after the German Covid-19 vaccine maker reported sharp drop in profit and revenues for the second quarter. However, the company recorded strong growth in first-half results. Further, the company maintained BioNTech COVID-19 vaccine revenue guidance
Follow RTT